Cargando…

Response and resistance to BRAF(V600E) inhibition in gliomas: Roadblocks ahead?

BRAF(V600E) represents the most common BRAF mutation in all human cancers. Among central nervous system (CNS) tumors, BRAF(V600E) is mostly found in pediatric low-grade gliomas (pLGG, ~20%) and, less frequently, in pediatric high-grade gliomas (pHGG, 5-15%) and adult glioblastomas (GBM, ~5%). The in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capogiri, Monica, De Micheli, Andrea J., Lassaletta, Alvaro, Muñoz, Denise P., Coppé, Jean-Philippe, Mueller, Sabine, Guerreiro Stucklin, Ana S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868954/ https://www.ncbi.nlm.nih.gov/pubmed/36698391 http://dx.doi.org/10.3389/fonc.2022.1074726

Ejemplares similares

LGG-08. TARGETED THERAPY IN BRAF(V600E)-DRIVEN PEDIATRIC GLIOMAS: UNCOVERING MECHANISMS OF RESISTANCE THROUGH A MULTI-OMIC APPROACH
por: Capogiri, Monica, et al.
Publicado: (2023)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Resistance mechanisms in BRAF(V600E) paediatric high-grade glioma and current therapeutic approaches
por: Lehmann, R., et al.
Publicado: (2022)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
por: Di Nunno, Vincenzo, et al.
Publicado: (2023)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

BRAF (AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF (V600E)
por: Da, Rong, et al.
Publicado: (2021)

Successes and challenges in modeling heterogeneous BRAF(V600E) mutated central nervous system neoplasms
por: Xing, Yao Lulu, et al.
Publicado: (2023)

Children, HIV, emergencies and Sustainable Development Goals: roadblocks ahead and possible solutions
por: Chamla, Dick, et al.
Publicado: (2018)

Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults
por: Weiser, Annette, et al.
Publicado: (2023)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

DRP1 Promotes BRAF(V600E)-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer
por: Padder, Rayees Ahmad, et al.
Publicado: (2021)

Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases
por: Xia, Rong-Hui, et al.
Publicado: (2021)

Metanephric stromal tumor with BRAF V600E mutation in an adult patient: Case report and literature review
por: Fan, Yuqian, et al.
Publicado: (2022)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors
por: Ruiz-Saenz, Ana, et al.
Publicado: (2023)

Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis
por: Kang, Keiko M., et al.
Publicado: (2021)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
por: Liu, Chaoyuan, et al.
Publicado: (2022)

Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
por: Fusco, Michael J., et al.
Publicado: (2021)

LGG-23. OUTCOMES UTILIZING BRAF INHIBITION MONOTHERAPY IN BRAF(V600E) MUTATED PEDIATRIC LOW GRADE GLIOMAS
por: McThenia, Sheila, et al.
Publicado: (2023)

EGFR blockade prevents glioma escape from BRAF(V600E) targeted therapy
por: Yao, Tsun-Wen, et al.
Publicado: (2015)

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
por: Burger, Michael C., et al.
Publicado: (2017)

HGG-02. ADOLESCENT AND YOUNG ADULT (AYA) GLIOMA WITH BRAF V600E-MUTANTATION
por: Kimura, Yui, et al.
Publicado: (2020)

HGG-13. ONCOGENIC STAT3 AND SHP2 ACTIVATION IN ROS1-FUSION DRIVEN INFANT-TYPE HEMISPHERIC GLIOMAS
por: Postlmayr, Andreas, et al.
Publicado: (2023)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency
por: Christenson, Eric S., et al.
Publicado: (2023)

METB-02. DECIPHERING THE CELLULAR HETEROGENEITY OF INFANT-TYPE HEMISPHERIC GLIOMAS USING SINGLE-NUCLEI MULTI-OMICS
por: De Micheli, Andrea J, et al.
Publicado: (2023)

Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
por: Garnier, Louis, et al.
Publicado: (2019)

Multidisciplinary Therapy Managed Recurrent Glioblastoma in a BRAF-V600E Mutant Pregnant Female: A Case Report and Review of the Literature
por: Qin, Chaoying, et al.
Publicado: (2020)

GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAF(V600E) Colorectal Cancer
por: Zhang, Ruowen, et al.
Publicado: (2020)

Diagnostic Efficacy of Ultrasound, Cytology, and BRAF(V600E) Mutation Analysis and Their Combined Use in Thyroid Nodule Screening for Papillary Thyroid Microcarcinoma
por: Du, Jing, et al.
Publicado: (2022)

Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case
por: Yang, Tian, et al.
Publicado: (2021)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

Sustained response of three pediatric BRAF(V600E) mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy
por: Toll, Stephanie A., et al.
Publicado: (2019)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF(V600E) Mutations
por: Su, Yanjun, et al.
Publicado: (2021)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
por: Consoli, Francesca, et al.
Publicado: (2020)

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis
por: Hong, Ling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_45m28se5g2hjhku4rnusvgd77r